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A B S T R A C T
Antipsychotic drugs have been increasingly prescribed to children and adolescents for treating various mental
disorders, such as childhood-onset schizophrenia. The abnormality of endocannabinoid system is involved in the
pathophysiology of these disorders in juveniles. This study investigated the effect of antipsychotics on the
cannabinoid (CB) receptors in the brain of both male and female juvenile rats. The postnatal rats (PD23±1)
were administered aripiprazole (1 mg/kg), olanzapine (1mg/kg), risperidone (0.3mg/kg) or vehicle (control)
for 3 weeks. Quantitative autoradiography was used to investigate the binding densities of [3H]CP-55940 (an
agonist for CB1R and CB2R) and [3H]SR141716A (a selective CB1R antagonist) in the rat brains. Risperidone
significantly upregulated the [3H]CP55940 and [3H]SR141716A bindings in the prefrontal cortex (PFC), nucleus
accumbens core (NAcC), nucleus accumbens shell (NAcS), cingulate cortex (Cg), and the caudate putamen (CPu)
in male rats. Moreover, aripiprazole significantly elevated the [3H]SR141716A binding in the Cg and NAcS of
female rats. Furthermore, there is an overall higher [3H]SR141716A binding level in the brain of female rats
than male rats. Therefore, treatment with aripiprazole, olanzapine and risperidone could induce differential and
gender specific effects on the binding density of cannabinoid receptors in the selected brain regions of child-
hood/adolescent rats.
1. Introduction
In recent years, prescriptions of atypical antipsychotic drugs (APDs)
(mostly off-label use, particularly olanzapine, risperidone and ar-
ipiprazole), in children and adolescents have been dramatically in-
creased for treating various mental disorders, such as childhood-onset
schizophrenia, bipolar disorder, autism, attention deficit hyperactivity
disorder, and Tourette's disorder (Ronsley et al., 2013). These APDs
target multiple neurotransmission receptors, particularly dopamine D2
and serotonin (5-HT)2 receptors to achieve their therapeutic action
(Ginovart and Kapur, 2012; Meltzer and Massey, 2011). Olanzapine and
risperidone are antagonists at these neurotransmission receptors
(Correll, 2010), while aripiprazole is a partial agonist of the dopamine
D2 and 5-HT1A receptors, a partial antagonist of the 5-HT2A receptor,
and is sometimes defined as a D2 receptor (D2R) functional selective
drug (Di Sciascio and Riva, 2015; Levoyer et al., 2007; Mailman, 2007;
Mailman and Murthy, 2010). It is important that those receptors also
play crucial roles in neurodevelopment and almost all of the core brain
functions (Ginovart and Kapur, 2012; Meltzer and Massey, 2011).
Childhood-adolescence is a critical period of neural development,
with sculpting of the neuronal pruning, apoptosis and myelination
(Schneider, 2008). Substances, such as APD treatment, during this
crucial neurodevelopmental period may impact brain maturation and
plasticity in brain neurotransmission (Ronsley et al., 2013; Schneider,
2008). Cannabinoid receptor mediates physiological and behavioural
effects of natural and synthetic cannabinoids (Herkenham et al., 1991).
It has been shown that developmental exposure to cannabinoids may
induce subtle and long-lasting neuro-functional alterations (Trezza and
Vanderschuren, 2008). Moreover, it has been indicated that the en-
docannabinoid CB1 receptors (CB1R) and their endogenous ligands are
expressed in the early brain development period in rodents
(Vitalis et al., 2008). The CB1R are widely distributed in the cerebral
cortical brain regions of both humans and rats, including the prefrontal
cortex (PFC), cingulate cortex (Cg), caudate putamen (CPu), and nu-
cleus accumbens (NAc) (Breivogel and Childers, 1998; Derbenev et al.,
2004). These brain regions are associated with the pathophysiology of
https://doi.org/10.1016/j.psychres.2018.03.030
Received 30 August 2017; Received in revised form 5 January 2018; Accepted 8 March 2018
⁎ Corresponding author at: Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia.
E-mail address: chao@uow.edu.au (C. Deng).
Abbreviation: 5-HT, serotonin; ADHD, attention deficit hyperactivity disorder; ANOVA, analysis of variance; APDs, antipsychotic drugs; BSA, bovine serum albumin; cAMP, cyclic
adenosine monophosphate; Cg, cingulate cortex; CPu, caudate putamen; CB1R, cannabinoids 1 receptor; CB2R, cannabinoids 2 receptor; D2R, D2 receptor; NAc, nucleus accumbens;
NAcC, nucleus accumbens core; NAcS, nucleus accumbens shell; PFC, prefrontal cortex; PD, postnatal day; RT, room temperature; SEM, standard error of mean
Psychiatry Research 266 (2018) 317–322
Available online 16 March 2018
0165-1781/ © 2018 Elsevier B.V. All rights reserved.
T
childhood schizophrenia, bipolar disorder, autism, and attention deficit
hyperactivity disorder (ADHD) (Almeida et al., 2014; Zavitsanou et al.,
2004), as well as the action of APDs (Cheng et al., 2008), but not in-
volved directly in body weight regulation (Theisen et al., 2007). The
elevation of CB1R binding was observed in the prefrontal area of brains
from schizophrenic and other mental disorder patients (Ceccarini,
2014; Dalton et al., 2011; Jenko et al., 2012) Therefore, the en-
docannabinoid system plays a vital role in brain development and the
pathology of various mental disorders (Renard et al., 2014), and con-
tributes to the efficacy of APDs (Berk et al., 1999; Sundram et al.,
2005).
Except for the endocannabinoid CB1R, the brain regions, including
the PFC, Cg, CPu, and NAc also contain high levels of dopamine and 5-
HT receptors; in these brain regions there are interactions between the
monoamine neurotransmitters and the endocannabinoid system
(Hermann et al., 2002; Wiley et al., 2008). The dopamine and 5-HT
receptors are located in the mesocortical, mesolimbic and nigrostriatal
pathways, which contribute to the effects of APDs on the function of
cognition, affect and motor, respectively (Glass et al., 1997; Wiley et al.,
2008). A number of studies have suggested the interaction between
cannabinoid receptors and dopamine/5-HT receptors. As a selective
CB1R antagonist, SR141716A upregulated the expression of dopamine,
5-HT, and noradrenaline in the PFC of rats (Tzavara et al., 2003). In the
primary cell culture of striatal neurons, both the CB1R agonist HU210
and the D2R agonist quinpirole inhibited forskolin-stimulated cyclic
adenosine monophosphate (cAMP) accumulation when applied sepa-
rately, while HU210 and quinpirole in combination augmented cAMP
accumulation, which was blocked by the CB1R antagonist SR141716A
or the D2R antagonist sulphide (Glass et al., 1997). One previous study
in the rat brain showed that the D2R level could be reduced by
SR141716A through the CB1R in the extrapyramidal system
(Alonso et al., 1999). On the other hand, it was reported that neuro-
logical and psychiatric disorders are often associated with long-term
impairment of serotonergic and endocannabinoid control of synaptic
plastic in the PFC (Ferreira et al., 2012). This is partially attributed to
the highly overlapping distribution pattern of the cannabinoid CB1R
and 5-HT receptors in the brain (Hermann et al., 2002). The previous
study from our group reported that early treatment with various APDs
had different effects on the 5-HT and dopamine receptors with some
gender-dependent changes (Lian et al., 2016). It has been suggested
that APDs increased CB1R availability in schizophrenia patients
(Ranganathan et al., 2016). Therefore, APDs may regulate cannabinoid
receptors through dopamine or serotonin neurotransmission.
It is worth noting that the onset of schizophrenia and bipolar dis-
order often occurs during late adolescence; therefore, evaluation of APD
interaction with the endocannabinoid system in adolescents is indis-
pensable (Wiley et al., 2008). Thus, to determine the effects of the APDs
olanzapine, risperidone and aripiprazole on the endogenous cannabi-
noid system in the adolescent rat brain, the binding density of the
cannabinoid CBR in the PFC, CPu, and NAc of adolescent rats was
measured after 3 weeks’ APD treatment.
2. Method
2.1. Animals, diet and experimental procedures
Timed pregnant Sprague Dawley rats (at gestation day 16) were
obtained from the Animal Resources Centre (Perth, WA, Australia).
They were housed in individual cages and allowed ad-libitum access to
standard laboratory chow diet (3.9 kcal/g: 10% fat, 74% carbohydrate,
16% protein) and water under a light (07:00 to 19:00) and dark (19:00
to 7:00) cycle and temperature control (22 °C) throughout the experi-
ment (Deng et al., 2012; Lian et al., 2014). Day of birth was recognised
as postnatal day (PD) 0. Pups were sexed on PD14, and 24 male and
female rats were weaned on PD21 and housed in individual cages.
Before the treatment procedures, rats were trained for self-
administration of the drug by feeding them using 0.3 g cookie dough
(including 30.9% cornstarch, 30.9% sucrose, 6.3% gelatine, 15.5%
casein, 6.4% fibre, 8.4% minerals and 1.6% vitamins) without drug
twice a day during PD18-21. There were four treatment groups: (1)
Aripiprazole (1 mg/kg, 3 times/day, Otsuka, Japan; n= 6), (2)
Olanzapine (1mg/kg,3 times/day, Eli Lilly, USA; n= 6), (3)
Risperidone (0.3 mg/kg, 3 times/day, Janssen, USA; n= 6) or (4)
Vehicle (control; n= 6) for 3 weeks (a period corresponding to the
childhood-adolescence period in humans) (Andersen, 2003). Drugs
were prepared in advance by mixing with cookie dough pellets and
droplets of water, and were administered 3 times per day (8 ± 1 h
intervals) orally for 3 weeks (Lian et al., 2014). The rats in the control
group received an equivalent pellet without drug. Rats were observed
throughout the experiment to ensure all cookie dough pellets were
consumed. This study was approved by the Animal Ethics Committee,
University of Wollongong, Australia (AE12/20); and all the procedures
complied with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (2004).
2.2. Histological procedures
Forty eight hours after the last drug treatment, the rats were sa-
crificed, their brain tissue was removed and frozen in liquid nitrogen,
and then stored at −80 °C until analysis. Brains were coronally sec-
tioned at −18 °C into 14 µm using a cryostat (Leica CM1850, Leica
Microsystem, Germany). Sections were thaw-mounted onto Polysine™
Microscope Slides (Menzel GmbH & Co. KG, Braunchweig, Germany)
and stored at −20 °C. A set of sections from each animal was stained
with 0.5% cresyl violet solution (Nissl staining) and used to confirm
anatomical structures.
2.3. [3H]CP-55940 binding
The cannabinoid receptor binding was performed using [3H]CP-
55940 (an agonist to CB1R and CB2R) as previously described
(Deng et al., 2007). Briefly, brain sections containing the PFC, Cg, NAc
and CPu were thawed at room temperature (RT), and after 30min of
pre-incubation in 50mM Tris buffer (pH 7.4) containing 5% bovine
serum albumin (BSA), they were incubated with 10 nM[3H]CP-55940
(specific activity: 67 Ci/mmol; ki: 1.07 nM; PerkinElmer, USA) in
50mM Tris buffer containing 5% BSA for 2 h at RT to determine total
binding. Non-specific binding was determined by incubating the next
sequential sections with 10 nM [3H]CP-55940 incubation buffer, with
the addition of 10 μM CP-55940 (Sigma Pharmaceuticals, Australia).
Slides were washed for 5min in ice-cold buffer, dipped in ice-cold
distilled water, and then dried under a stream of cool air to remove
excess buffer salts (Weston-Green et al., 2008).
2.4. [3H]SR141716A binding
In brief, binding of [3H]SR141716A (a CB1R selective antagonist,
specific activity: 20.8 Ci/mmol, PerkinElmer, USA) using [3H]
SR141716A was performed based on procedures previously described
(Deng et al., 2007). In brief, sections were pre-incubated in 50 nM Tris
buffer including 5%BSA (pH 7.4) for 15min at RT. Sections were then
incubated for 1 h at RT in the same buffer containing 1.5 nM [3H]
SR141716A (specific activity: 67 Ci/mmol; ki: 2.04 nM; Amersham, UK)
and 0.1% bovine serum albumin (BSA) for the total binding. Non-spe-
cific binding was determined with the addition of 100 μM HU210. After
incubation, the sections were washed in ice-cold buffer containing 0.1%
BSA (2×30min), dipped in distilled water and air dried (Deng et al.,
2007).
2.5. Autoradiography and quantification of cannabinoid receptor binding
All of the receptor binding slides were exposed to Kodak BioMax MR
J. Lian, C. Deng Psychiatry Research 266 (2018) 317–322
318
film for 3 months, together with autoradiographic standards ([3H]mi-
croscales from Amersham), in X-ray film cassettes. This is allowed by
the analysis of binding images using the Multi-analyst image analysis
system (Bio-Rad, USA). The specific binding was calculated by de-
ducting nonspecific binding from total binding. A set of sections from
each animal were stained with 0.5% cresyl violet solution (Nissl
staining) and used to confirm anatomical structures. Specific brain re-
gions in this project were identified by reference to the Nissl-stained
sections and a standard rat brain atlas (Paxinos and Watson, 2007).
2.6. Statistical analysis
Statistical analysis was performed using SPSS (IBM version 21.0,
SPSS Inc., NY, USA). The Kolmogorov-Smirnov test was used to ex-
amine the distribution of data from all experiments. The receptor
binding density in relevant rat brain regions was analysed by two-way
ANOVAs (Treatment × Gender). Post-hoc Dunnett-T tests allowed for
comparison between groups and the Mann-Whitney U test was applied
to the data without abnormal distribution. All data are expressed as
mean ± SEM, and statistical significance will be accepted when
p<0.05.
3. Results
3.1. [3H]CP-55940 binding
Examples of [3H]CP-55940 binding to cannabinoid receptors are
presented in Fig. 1 (C and D). Two-way ANOVAs revealed the
significant effects of the Treatment factor on [3H]CP-55940 binding in
the PFC (F3,40= 3.863, p=0.016), Cg (F3,40= 3.682, p=0.020), NAc
core (NAcC) (F3,40= 3.771, p=0.018), NAc shell (NAcS)
(F3,40= 2.875, p=0.048), and CPu (F3,40= 3.721, p=0.019). Al-
though there was no significant effect of the Gender factor in these
brain nuclei, there was significant interaction between the two factors
in the PFC (F3,40= 4.543, p=0.008). In the male rats, risperidone
treatment significantly increased the levels of [3H]CP-55940 binding
density (Fig. 1). Post hoc analysis identified a significant increase in
[3H]CP-55940 binding density in the PFC, NAcC (p<0.01) and Cg,
CPu and NAcS (p<0.05) in the rats receiving the risperidone treatment
(Fig. 2). However, there was no significant difference between treat-
ment groups in female rats (all p>0.05) (Fig. 2).
3.2. [3H] SR141716A binding
Examples of [3H]SR141716A binding to CB1R are presented in
Fig. 1 (E and F). Overall, female adolescent rats had a higher CB1R
binding density in the Cg (F1,40= 12.488, p=0.001), NAcC
(F1,40= 10.297, p=0.003), NAcS (F1,40= 9.786, p=0.003), and CPu
(F1,40= 8.825, p=0.005) than the males. The significant effect of the
Treatment factor was also observed in the PFC (F3,40= 4.082,
p=0.013). Risperidone significantly increased [3H]SR141716A
binding in the PFC, NAcC, NAcS (p<0.05), and CPu (p<0.01)
(Fig. 3). Aripiprazole treatment significantly upregulated the [3H]
SR141716A binding in the Cg and NAcS (p<0.05) of female rats.
There were significant differences between male and female rats by
[3H]SR141716A binding in the Cg, PFC, NAcC, NAcS and CPu (all
Fig. 1. Examples of [3H]CP55940 and [3H]SR141716A bindings in the rat brain. A-B, The schematic diagram is adapted from a rat brain atlas (Paxinos and Watson, 2007) showing the
level of Bregma 4.68 mm (A) and 1.08 mm (B). C–D, examples of autoradiograms to show [3H]CP5594 binding (from the non-treatment group of male rats). E–F, examples of [3H]
SR141716A binding (from the non-treatment group of female rats). G–H, examples of the non-specific bindings from male and female rats, respectively. Abbreviations: PFC, prefrontal
cortex; Cg, cingulate cortex; CPu, caudate putamen; NAcC, nucleus accumbens core; NAcS, nucleus accumbens shell.
J. Lian, C. Deng Psychiatry Research 266 (2018) 317–322
319
p< 0.05) with aripiprazole treatment (Fig. 3), while the clear differ-
ence between males and females was observed in the Cg, NAcC, NAcS,
and CPu with olanzapine treatment (p< 0.05) (Fig. 3).
4. Discussion
This study investigated the effects of olanzapine, risperidone and
aripiprazole treatment during PD22-42 (a period corresponding to the
childhood-adolescence period in humans) on the binding of
[3H]CP55940 and [3H]SR141716A for cannabinoids receptors in se-
lected brain regions of both male and female adolescent rats. To our
knowledge, this is the first study to examine the effects of APDs on
cannabinoid receptors in both adolescent male and female rats using
the two cannabinoid ligands. The two cannabinoid receptor bindings
showed different binding patterns in these brain regions.
The endocannabinoids CB1R and CB2R are present from the early
stages of gestation and play a number of vital roles for the developing
organism (Fride, 2004). The roles of endocannabinoid CB1R in the
developing organism include embryonal implantation, neural devel-
opment, neuroprotection, initiation of suckling in the newborn, while
they also contribute to memory, motor and addictive behaviours and
the pathogenesis of various mental disorders (Fride, 2004; Ujike and
Fig. 2. The effects of aripiprazole, olanzapine, and risperidone treatment on [3H]CP55940 binding (nCi/mg tissue) in (A) the prefrontal cortex (PFC), (B) cingulate cortex (Cg), (C)
nucleus accumbens, core (NAcC), (D) nucleus accumbens, shell (NAcS) and (E) caudate putamen (CPu) of both male and female adolescent rats (n=6/group). Data shown are the mean
values± SEM. *p<0.05, **p<0.01 vs. control.
Fig. 3. The effects of aripiprazole, olanzapine, and risperidone treatment on [3H]SR141716A binding (nCi/mg tissue) in (A) the prefrontal cortex (PFC), (B) cingulate cortex (Cg), (C)
nucleus accumbens, core (NAcC), (D) nucleus accumbens, shell (NAcS) and (E) caudate putamen (CPu) of both male and female adolescent rats (n=6/group). Data shown are the mean
values± SEM. *p<0.05, **p<0.01 vs. control. #p<0.05, male vs. female. t(*)0.05< p<0.1 vs. control.
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Morita, 2004). CB2Rs are primarily located on immune cells, and play
important roles in cell-mediated and humoral immunity, and neuroin-
flammation, while they are also expressed in the brain and contribute to
neuronal and functional expression (Cabral and Griffin-Thomas, 2009;
Onaivi et al., 2006; Onaivi et al., 2012). One post-mortem study with a
radioligand showed the differences in the levels of [3H]CP55940
binding in the dorsolateral PFC, CPu and hippocampus of 14 schizo-
phrenic patients compared with controls (Dalton et al., 2011). There-
fore, it is important to investigate the modulation of early APD treat-
ments on cannabinoid receptor development, which may be implicated
in treatment for various mental disorders in adolescents, although APDs
such as olanzapine exhibited negligible affinities to CB1R
(Theisen et al., 2007).
This study suggest that risperidone administration significantly
upregulated the [3H]CP55940 bindings in all brain regions examined in
male adolescent rats. In line with our findings, a previous study also
revealed that risperidone treatment increased cannabinoid receptor
bindings using [3H]CP55940 in the NAc of male rats (Secher et al.,
2010). It was also reported that increased binding by [3H]CP55940
occurred in the NAc after prolonged clozapine treatment of rats
(Sundram et al., 2005). Another previous study reported olanzapine
enhanced the [3H]CP55940 binding in the NAc of adult male rats
(Sundram et al., 2005). Although the same olanzapine dosage was used
in those studies (1mg/kg), there was no effect of early olanzapine
treatment on [3H]CP55940 binding observed in any brain region of
adolescent rats, which may be due to the different age of the rats
(adolescent rats in this study vs. 6-weeks in Sundram's study), and
administration method (mini-pump without drug washout period in
Sundram's study, vs. cookie dough with drug washout period in this
study). The above age difference result was also supported by the
previous study, in that the change of cannabinoid CB1R in the brain is
related to the age of the rats (Liu et al., 2003). It is interesting that, in
this study, APDs did not affect [3H]CP55940 binding in female rats.
Although the [3H]CP55940 binds to both CB1 and CB2 receptors, its
binding affinity to the CB1R is approximately 100 times higher than
that of the CB2R (Onaivi et al., 2006). This suggests risperidone ele-
vated mainly CB1R in these brain regions; however, the roles of CB2R
could not be completely excluded. Previous studies have reported that
brain CB2R is involved in neurophysiological functions including
modulating midbrain dopamine neuronal activity, dopamine-related
behaviour, and hippocampal synaptic transmission (Li and Kim, 2016).
Deletion of CB2R induced long-term memory deficit and schizophrenia-
like behaviours in mice (Li and Kim, 2016; Ortega-Alvaro et al., 2011).
There are also genetic associations between polymorphism of CNR2
gene (encoding for CB2R) and neuropsychiatric disorders with in-
creased risk of autism spectrum disorders, bipolar disorders, depression,
drug abuse, schizophrenia (Ishiguro et al., 2010; Minocci et al., 2011;
Onaivi et al., 2013). Therefore, it is important for further studies to
investigate the effects of APDs on CB2R using selective CB2R ligands
such as HU910, HU308 or JWH133 (Soethoudt et al., 2017).
These results were confirmed by binding of a selective CB1R ligand
[3H]SR141716A. Consistently with the [3H]CP55940 binding, risper-
idone also increased the [3H]SR141716A binding level in the PFC, NAc,
CPu and Cg of male rats. The elevated [3H]SR141716A bindings was
also observed in the NAcS, and PFC of female rats, compared to controls
after aripiprazole administration. There were higher [3H]SR141716A
binding levels in the PFC, Cg, NAcC, NAcS, and CPu of female rats, than
those of male rats, after aripiprazole treatment. To the best of our
knowledge, this is the first study to investigate the effect of APDs on
[3H]SR141716A in adolescent subjects. Since [3H]SR141716A is a
specific CB1R ligand, this suggests that risperidone increases mainly the
CB1R binding level in these brain regions. Although [3H]CP55940
showed gender difference in the effect of risperidone treatment, gender
difference was more obvious in [3H]SR141716A bindings a higher [3H]
SR141716A binding in female rats. This may be attributed to the spe-
cific CB1R binding profile for [3H]SR141716A, compared to
[3H]CP55940, which binds to both CB1R and CB2R. It is important to
note that the gender difference has often been observed in children and
adolescents with mental disorders (Rapado-Castro et al., 2015;
Rucklidge, 2010; Society, 2017), as well as antipsychotic effects (Haack
et al., 2009; Rubin et al., 2008). However, olanzapine had no effect on
the [3H]SR141716A binding for female rats, compared to controls.
The CB1Rs are present on serotonergic and dopaminergic neurons
both in soma and synaptic terminals and modulate neurotransmission
(Lau and Schloss, 2008). Therefore, APDs like risperidone and ar-
ipiprazole may modulate the endocannabinoid system via other neu-
rotransmitters, such as dopamine and 5-HT. The cannabinoid ligands
could modulate dopaminergic neurotransmission in the PFC, the
striatum and the mesolimbic system (Patel and Hillard, 2003; Tzavara
et al., 2003), which are associated with schizophrenia (Abi-Dargham
and Moore, 2003; Madsen et al., 2006). It was reported that adminis-
tration of the D2R antagonist raclopride increased anandamide levels,
and led to compensatory upregulation of CB1R, which attenuated ex-
cessive dopamine signalling, indicating the therapeutic implication for
APD treatment (Secher et al., 2010). Our previous study illustrated the
dopamine receptor change by APD administration, in that aripiprazole
administration significantly decreased dopamine D1R, but not D2R
binding density in the PFC of male rats (Lian et al., 2016). The
SR141716A, as the CB1R antagonist, was reported to increase the levels
of serotonin and dopamine in the forebrain involved in the control of
these monoamines by CB1R (Darmani et al., 2003). Furthermore, CB1R
has also been reported to regulate 5-HT2A/C receptor mediated beha-
viours, possibly through serotonin regulation (Darmani et al., 2003;
Secher et al., 2010). Therefore, APDs may indirectly modulate the CB1R
via dopaminergic and 5-HTeric neurotransmission. Overall, it is pro-
posed that APDs affecting either system might have indirect effects on
the other.
In this study, rats were sacrificed 48 hours after last dose of APDs is
to allow for further clearance of any residual drugs to avoid their direct
interference with [3H]CP55940 and [3H]SR141716A binding. Due to
the experimental limitation there were not enough brain samples to
measure APD concentrations in this study, however it has been reported
that the half-lives of olanzapine, risperidone, aripiprazole in rat brain
are 5.1 h, 13.6 h, and 2 h, respectively, while the half-lives of these
drugs in rat plasma are 2.5–3.5 h, 12.4 h, 2 h (Aravagiri and Marder,
2002; Aravagiri et al., 1999; Feltenstein et al., 2009; Liu et al., 2015).
Based on their half-lives in the rat brain, after 48 hours drug wash-out
period, very limited amount of APDs will be remained in the rat brain.
Furthermore, these APDs have negligible affinities with CB receptors
(Correll, 2010; Theisen et al., 2007). Therefore, the changes in CB1R
binding observed in this study would not be the direct effect of APDs,
but CB1R neuroadaptations after 3 weeks treatment with these drugs. It
should also be aware that the other limitation of this study was without
measuring the behavioural and physiological changes, it is important
for further studies to investigate the relationships of these CB1R binding
changes with the potential behavioural and physiological changes in
rats.
In summary, this study observed that treatment with APDs in-
cluding aripiprazole, olanzapine and risperidone induces differential
expression of cannabinoids CB1R in the selected brain regions of
childhood/adolescent rats with gender differences. This study showed
the different effect of various APDs on [3H]CP55940 and [3H]
SR141716A bindings in various brain regions, which suggest that early
APD treatment modulates cannabinoid receptors, particularly CB1R in
the brain of adolescents. Risperidone is the most frequently used APD
(∼70%) in children and adolescents, and its therapeutic efficacy to
control symptoms of mental disorders in children/adolescents may be
through modulating CB1R neurotransmission. Further studies should be
conducted to investigate the regional and symptom-specific alterations
of cannabinoid receptors in mental disorders, which may improve the
treatment of APDs on children/adolescents.
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